CytomX Therapeutics (CTMX) IPO Prices at $12, Below Expected Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
CytomX Therapeutics (CTMX) IPO Opens Sharply Higher, Pares Gains
October 8, 2015 2:49 PM EDTToday's IPO for CytomX Therapeutics, Inc. (NASDAQ: CTMX) opened for trading earlier at $16 after pricing 6,666,667 shares of common stock at an initial public offering price of $12 per share, below the $14-$16 range. Shares have since backed down to $14.35.
In addition, the underwriters have a 30-day option to purchase up to an additional 1,000,000 shares of common stock from CytomX. All shares of common stock are being offered by CytomX.
BofA Merrill Lynch, Jefferies LLC and Cowen and... More
